ABSTRACT
KEY MESSAGES
 There are calls for widespread screening for Mycoplasma genitalium, but the natural history of this emerging sexually transmitted pathogen is poorly understood.
 M. genitalium incidence was 1.07 (95% confidence intervals, CI 0.61 to 1.53) per 100-person years in women in highly developed countries, 39-50% of infected individuals had a heterosexual partner with M. genitalium and the risk ratio for pelvic inflammatory disease was 1.68 (95% CI 0.59 to 2.77).
 The duration of untreated M. genitalium infection is probably longer than persistent detection of M. genitalium, as measured in most cohort studies, in which inadvertent treatment cannot be ruled out.
 The results of this systematic review and other evidence sources show important differences in the epidemiology and dynamics of M. genitalium and Chlamydia trachomatis infection.
INTRODUCTION
Mycoplasma genitalium is increasingly seen as an emerging sexually transmitted pathogen. [1] [2] [3] [4] [5] M. genitalium is a cause of non-gonococcal urethritis [1] and cervicitis [3] and associations with pelvic inflammatory disease (PID), other reproductive tract complications in women and adverse pregnancy outcomes have been found. [3] M. genitalium has thus been called the 'new chlamydia'. [6] In a previous systematic review, we found a prevalence of M.
genitalium of approximately 1% in sexually active heterosexuals in the general population, which is similar to that reported for Chlamydia trachomatis aged 16-44 years. [7] In sex workers, men who have sex with men (MSM) and clinic-based populations prevalence was higher and more variable. [8] The increasing availability of nucleic acid amplification tests (NAAT) that detect M. genitalium has resulted in calls for widespread testing of asymptomatic populations. [9] But increased testing and treatment is likely to exacerbate the already high proportion of antimicrobial resistant M. genitalium, since de novo resistance to macrolides emerges rapidly. [10 11] Mathematical modelling could help to understand the balance of benefits and harms that widespread testing and treatment interventions bring. [12] To develop mathematical models, we need robust empirical estimates about the dynamics and probability of progression to PID of M. genitalium infection. Important variables are in the following equations:
where R0 is the basic reproductive number, the average number of secondary infections spread by an infected individual; if R0 is greater than one, a pathogen can spread in the population. [13] These measures cannot all be observed directly, [14] but concordant M.
genitalium status between sexual partners can be used to derive the transmission probability [15] 
METHODS
This systematic review is one of two linked reviews that used a single search strategy and are described in two protocols. [18 19 ] A review of the prevalence of M. genitalium has been published. [8] We report our findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, online supplementary file 1). [20] 
Eligibility criteria
We included studies of M. genitalium detected by NAAT. Study populations were women and men older than 13 years of age in any country. Eligible study designs were: for incidence of M. genitalium, cohort studies with participants who were uninfected at baseline; for persistence, cohort studies that followed people with untreated M. genitalium infection; for concordance, cross-sectional studies which enrolled couples or sexual partners of index cases; for incidence of PID, cohort or nested case-control studies that compared women with and without M. genitalium.
Information sources and search strategy
We searched Medline and EMBASE databases, with no language restrictions from 1 January 1981 until 12 July 2016 and updated the search to 17 March 2018. We used thesaurus headings and free text terms that combined Mycoplasma and Mycoplasma genitalium with genital tract complications (online supplementary file 2, Text S1). We also searched the African Index Medicus, IndMED and LILACS, using the term Mycoplasma genitalium.
Records were managed using EndNote (version X8.1, Clarivate Analytics, Philadelphia, PA, USA).
Study selection
Abstracts published before 1 January 1991 were excluded. Two reviewers (MC, LB) assessed study eligibility independently, using a pre-piloted screening form. We resolved differences by discussion or adjudication by a third reviewer (NL). (Table S1 ).
Data collection
[8]
Risk of bias in individual studies
For cohort or nested case-control studies, we adapted a tool published by the Cochrane Bias Methods Group. [22] For cross-sectional studies, we applied a previously used checklist. genitalium infection at baseline.
Synthesis of results
We used Stata (version 13.1, StataCorp, College Station, TX, USA) for statistical analysis.
We examined data about incidence, concordance and PID in forest plots. We stratified studies reporting incidence according to the level of development of the country in which the study was conducted, categorised as very high, high, medium and low using the United Nations Development Programme Human Development Index (HDI conducted a subgroup analysis, using a test of interaction, of differences in concordance by study design.
Risk of bias across studies
We did not test for small study biases with funnel plots because of the small number of included studies.
RESULTS
We identified 4634 records and, after exclusion of duplicates and articles published before 1991, we screened 3820 records. We included 17 studies, some of which reported on more than one review question (Table 1 , Figure S1 ). Five studies reported on incidence, [6 26-29] five reported on persistence, [ 
Incidence
We included five studies (Table S2) , [6 26-29] with a total of 4100 female participants at baseline and follow-up of 3381.5 person-years. Two studies were conducted in countries with a very high HDI, in students (Great Britain 2) [6] and in attendees of primary health care clinics (Australia 3). [26] All three studies from countries with a low HDI were conducted in female sex workers in (Uganda 1, Kenya 2 and Kenya 3).[27 28 31] We excluded one study post-hoc; Balkus et al. reported combined incidence in women in the USA and Kenya, [43] but the results of the Kenyan cohort were described more extensively in the Kenya 3 study. [29] All women in the Uganda 1 study had a positive test for M. genitalium at baseline.
Incidence was defined as a positive test result in women who had a preceding negative test result. [28] All studies were at risk of bias (Table S3 ). All studies reported more than 20% loss to follow-up or did not report it. [6 26-29] Only one (Great Britain 2) compared participants followed up until the end of the studies and participants lost to follow-up.
[6] Figure 1 shows that, in countries with a very high HDI, the pooled estimate of incidence was 1.07 per 100 person-years (95% CI 0.61 to1.53, 2 studies, I 2 0%).[6 26] The incidence rates in studies conducted among female sex workers were higher and too heterogeneous to combine (I 2 96.7%). 
Persistent detection of M. genitalium
We included five publications,[6 27 28 30 31] with a total of 636 female participants at baseline (Table S4) . Three studies were conducted in female sex workers in Kenya and any of the studies. All studies were at risk of bias in outcome assessment (Table S5 ). In
Great Britain 2, women with a positive test result for C. trachomatis at baseline received antibiotics if they were in the intervention arm of the underlying randomised control trial but could have been treated before the 12-month follow up. In all other studies, participants received either syndromic treatment or treatment for diagnosed C. trachomatis, N.
gonorrhoeae and/or Trichomonas vaginalis at one to three month intervals. Only one study (Great Britain 2) distinguished persistent from re-infections with genotyping.
[6] Figure S2 shows a rapid decrease in the proportion of women infected in four studies.
Median persistence in the three studies of sex workers was one to three months. The Great genitalium and 40-50% in female partners of infected men, with no marked differences according to study design (Table S8) . Concordance among MSM (Australia 6) was 27%
(95% CI 19-36%).
[40]
Pelvic inflammatory disease
We included three prospective studies that examined the risk for PID in M. genitaliuminfected compared with non-infected participants, with a total of 5139 participants at baseline (Table S9 ). [6 41 42] The Great Britain 2 study enrolled female students in London,[6] USA 6 measured PID recurrence after treatment and cure of a first episode [41] and Sweden 10 was a nested case-control study in women who had undergone medical or surgical termination of pregnancy. [42] PID was diagnosed by endometrial biopsy in USA 6, and using clinical criteria in Great Britain 2 [6] and Sweden 10.
[41] Follow-up was six weeks in Sweden 10, [42] 12 months in Great Britain 2 [6] and 84 months, in USA 6. [41] All studies were at risk of bias (Table S10) . [6 41 42] None of the studies assessed if prognostic factors were similar between groups or compared individuals followed up with those lost to follow-up. 
DISCUSSION

Main findings
In this systematic review, the incidence of M. genitalium was 1.07 per 100 person-years (95% CI 0.61 to 1.53, I 2 0%, 2 studies) in women in very highly developed countries. Median duration of persistence of M. genitalium was one to three months in four studies but 15 months in one study. In ten studies measuring M. genitalium infection status in heterosexual couples, proportions of concordant results were 39 to 50%. In two prospective studies, the incidence of PID was higher in women with M. genitalium than those without (RR 1.68, 95%
CI 0.59 to 2.77, I 2 0%).
Strengths and limitations
A strength of our systematic review is the broad search strategy that covered differing topics, which makes it unlikely that we missed important relevant articles. In addition, selection of studies and extraction of data by independent reviewers reduces the risk of errors in data extraction. We assessed the risk of bias in all included studies. The relative importance of the domains of bias affect interpretation depend on the topic. For example, when measuring the duration of persistent detection, accurate assessment of the outcome, untreated infection is important, but most studies were at high risk of bias. The main limitations of the review findings result from the small number of studies overall and between study heterogeneity.
Interpretation of the findings
The findings of this review and our review of M. genitalium prevalence, [8] gives a systematic overview of several important aspects M. genitalium infection but reveals inconsistencies in the synthesised evidence about the prevalence, incidence and persistent detection of M.
genitalium infection (Table S11 ). Based on equation 1, the quotient of prevalence divided by incidence should be comparable for all studies, but the value obtained is more than one year for the Australia 3, [26] Great Britain 2 [6] and Uganda 1 [28] studies, and less than one year for Kenya 2 [27] and Kenya 3 [31] studies. For a sexually transmitted infection that is not highly transmissible to be able to persist (R0>1, equation 2) at a low prevalence in the general population, the duration of infectiousness has to be long. The prevalence of M.
genitalium in the general population of very highly developed countries is around 1%. [8] Concordance between sexual partners of 50% or lower ( Figure 3 ) suggest a low transmission probability. These characteristics are compatible with a longer, rather than a shorter, duration of infectiousness. In the Great Britain 2 and Uganda 1 studies, baseline prevalence was higher than incidence, resulting in an estimated duration of infection of more than one year (Table S11 ). The rationale and modelling analysis of Smieszek and White favoured a duration of infection similar to the Great Britain 2 study and suggested additional reasons for compatibility with the Uganda 1 study. [17] In all studies, women had opportunities for treatment with antibiotics with some activity against M. genitalium at frequencies of as little as a month. The duration of persistent detection was short in all studies that offered treatment every three months or more frequently. With probable inadvertent treatment and re-infection, these cohort studies did not measure the persistence of untreated infection. The uncertainty about the duration of infectiousness of M. genitalium contrasts with C. trachomatis, for which the literature is extensive and there is broad agreement that prevalence in general populations in high income countries is around 3-4%, [23] incidence is around 4% [44 45 ] and average duration of infectiousness is slightly more than one year. [46] The systematic review data suggest some possible differences between M. genitalium and 
